EFFECT OF LACOSAMIDE ON BEHAVIOUR OF CHILDREN WITH REFRACTORY PARTIAL EPILEPSY
Keywords:
Inclusion, Behavior, Prospective study, Lacosamide, InfluenceAbstract
Objective: A unicentre, prospective study was carried out to investigate the behavioral effects of lacosamide as adjunctive therapy with refractory partial epileptic children in tertiary care hospital with prior approval from the Institutional Human Ethical Committee.
Methods: Seventy nine patients (age 5- 15 years) with refractory partial epilepsy patients were enrolled after fulfilling the inclusion and exclusion criteria. And those who had failed ≥ 2 antiepileptic drugs in whom lacosamide was added as add on drug therapy. Lacosamide tablets was administered orally twice daily. Influence of Lacosamide on children's behaviour was performed at every visit of titration, maintenance period and 2 follow ups at monthly interval. Patient's caregiver or investigator observed adverse events were recorded.
Results: Out of 79 patient's, 53 were males and 26 females. Patients completing 3 months, of study therapy showed significant (p<0.001) decrease in frequency of seizure and improvement in behaviour at end of the treatment period and few patients had mild transient adverse events. Three patients were dropped from the study.
Conclusion: Lacosamide signifies a beneficial drug that is effective and concurrently improved patient's behaviour in refractory partial epilepsy paediatric patients.
Downloads
References
Commission on classification and terminology of the international league against epilepsy. Proposal for revised clinical and EEG classification of epileptic seizures. Epilepsia 1981;22:489–501.
Commission on classification and terminology of the international league against epilepsy. Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia 1989;30:389–99.
Cockerell OC, Johnson AL, Sander JWAS, Shorvon SD. Prognosis of epilepsy: a review and further analysis of the first nine years of the british national general practice study of epilepsy, a prospective population-based study. Epilepsia 1997;38:31–46.
Cockerell OC, Johnson AL, Sander JWAS, Hart YM, Goodridge DM, Shorvon SD. Mortality from epilepsy: results from a prospective population-based study. Lancet 1994;344:918–21.
Mrinal KR, Dhiman Das. Indian Epilepsy guidelines Chapter 2014;116:527-32.
Hanna NJ, Black M, Sander JW, Smithson H, Appleton R, Brown S, et al. The national sentinel clinical audit of epilepsy–related death: epilepsy-death in the shadows. Norwich: The Stationery Office, 2002. URL: http://www.sudep.org. [Accessed February 2003].
Sander JWAS, Hart YM, Johnson AL, Shorvon SD. National general practice study of epilepsy: newly diagnosed epileptic seizures in a general population. Lancet 1990;336:1267–71.
Wallace H, Shorvon S, Tallis R. Age specific incidence and prevalence rates of treated epilepsy in an unselected population of 2,052,922 and age-specific fertility rates of women with epilepsy. Lancet 1998;352:1970–3.
Clinical Standards Advisory Group. Services for patients with epilepsy. London: HMSO; 1999
Hart Y, Shorvon SD. The nature of epilepsy in the general population. II. Medical care. Epilepsy Res 1995;21:51–8.
British Medical Associated, Royal pharmaceutical Society of Great Britain. British National Formulary. 44th edn. London: British Medical Association and Royal of pharmaceutical Society Great Britain; 2002.
Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med 2000;342:314–9.
Diaz AR, Agostini MA, Van Ness PC. Evolving treatment strategies for epilepsy. JAMA 2002;287:2917–20.
Perucca E. Development of new antiepileptic drugs: challenges, incentives and recent advances. Lancet 2007;6:793–804.
Highlights of Prescribing Information of Lacosamide, UCB, Inc. Smyrna, GA; 2014.
Beyreuther BK, FreitagJ, Heers C, Krebsfanger N, Scharfenecker U, Stohr T. Lacosamide: a review of preclinical properties. CNS Drug Rev 2007;13:21–42.
Berg AT, Shinnar S. Newly diagnosed epilepsy in children: presentation at diagnosis. Epilepsia 1999;40:445–52.
Conners CK. Conner’s Comprehensive Behavior Rating Scales. Multi-Health Systems Inc; 2007.
Ismail Pasha, Mahesh Kamate, Suresh DK. Efficacy and Tolerability of Lacosamide as an adjunctive therapy in pediatric patients with refractory partial epilepsy. Pediatric Neurology; 2014. p. 1-6.
Berg AT, Ingrid ES. New concepts in classiï¬cation of the epilepsies: Entering the 21st century. Epilepsia 2011;52:1058–62.
Fattore C, Perucca E. Novel medications for epilepsy. Drugs 2011;71:2151-78.
Halasz P. Adjunctive lacosamide for partial-onset seizures: efficacy and safety results from a randomized controlled trial. Epilepsia 2009;50:443-53.
Chung S. Lacosamide as adjunctive therapy for partial onset seizures: a randomized controlled trial. Epilepsia 2010;51:958-67.
Chung SS. New treatment option for partial-onset seizures: efficacy and safety of lacosamide. Ther Adv Neurol Disord 2010;3:77-83.
Buck ML, Goodkin HP. Use of lacosamide in children with refractory epilepsy. J Pediatr Pharmacol Ther 2012;17:211-9.
Guilhoto LM. Experience with lacosamide in a series of children with drug-resistant focal epilepsy. Pediatric Neurol 2011;44:414–9.
Heyman E, Lahat E, Levin N, Berkovitch M, Marton RG. Preliminary efficacy and safety of lacosamide in children with refractory epilepsy. Eur J Paediatric Neurol 2012;16:15–9.
Fernandez CC. Efficacy and tolerability of lacosamide in the concomitant treatment of 130 patients under 16years of age with refractory epilepsy: a prospective, open-label, observational, multicentre study in Spain. Drugs RD 2012;12:187-97.
Ismail P, Mahesh K, Suresh DK. Reversible Inattention and hyperactivity in a child on Lacosamide: In south Indian Subpopulation. IOSR J Pharm Biol Sci 2014;9:66-7.